- First Unyvero™ Systems installed for clinical evaluation
- Presentation at 23rd National Congress on Lung Diseases in Kazan
Curetis AG today announced that its Unyvero™ System and its Unyvero™ P50 Application have been registered and cleared by the Russian and Serbian Ministry of Health, respectively.
The first Unyvero™ System has already been installed for approbation at the Central Clinical Hospital of the Presidential Administration of the Russian Federation in Moscow and another will be tested at one of the major hospitals in St. Petersburg.
Curetis´ distribution partner, BioLine LLC, is currently presenting the Unyvero™ System at major clinical and scientific events in Russia. Likewise, Curetis’ distribution partner Ako med d.o.o. is demonstrating the Unyvero™ System at major hospitals in Serbia, Bosnia Hercegovina, Croatia and Slovenia. » Read more...
- Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested together with chemotherapy in women with HPV16-positive advanced or recurrent cervical cancer -
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in women with HPV16-positive advanced or recurrent cervical cancer, eligible for standard chemotherapy with carboplatin and paclitaxel (CervISA study). The first patient was vaccinated this month.
ISA101 is a synthetic long peptide (SLP®) vaccine for the treatment of diseases induced by human papilloma virus (HPV) type 16, such as cervical cancer, ano-genital premalignant and malignant lesions, and head and neck cancer. » Read more...